Lamivudine
- Product NDC
- 51293-832
- 11-digit product format
- 512930832
- Labeler code
- 51293
- Product ID
- 51293-832_51880e6b-7586-4b33-9c28-f180764c899d
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Lamivudine
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- ECI Pharmaceuticals LLC
- Application
- ANDA203586
- Marketing category
- ANDA
- Marketing start
- 2018-06-15
- Marketing end
- 0000-00-00
- Substance
- LAMIVUDINE
- Active strength
- 150 mg/1
- Pharmacologic classes
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2021-12-31
- Current FDA listing
- Historical FDA.report record
FDA-Initiated Inactive NDC Indexing#
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 51293-832 | LAMIVUDINE TABLET [ECI PHARMACEUTICALS LLC] | 2 | Legacy NDC | 20200112_2d31d849-0882-4a71-b889-e57036e6fabe.zip |
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 51293-832-68 | 51293083268 | 60 TABLET in 1 BOTTLE (51293-832-68) | 60 tablet | 2018-06-15 | 0000-00-00 | No | No | Current |